[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 183,624,928
  • Shares Outstanding, K 1,239,955
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ -2,498 M
  • EBITDA $ 262 M
  • 60-Month Beta 0.32
  • Price/Sales 6.27
  • Price/Cash Flow 14.21
  • Price/Book 15.73

Options Overview Details

View History
  • Implied Volatility 27.21% (-0.59%)
  • Historical Volatility 25.77%
  • IV Percentile 21%
  • IV Rank 30.62%
  • IV High 40.29% on 10/13/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 1) 1.92 (1.30%)
  • Put/Call Vol Ratio 0.36
  • Today's Volume 444
  • Volume Avg (30-Day) 8,156
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 149,261
  • Open Int (30-Day) 167,316
  • Expected Range 145.62 to 149.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.15
  • Number of Estimates 6
  • High Estimate $2.30
  • Low Estimate $1.93
  • Prior Year $2.47
  • Growth Rate Est. (year over year) -12.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
128.28 +15.73%
on 07/30/26
149.62 -0.78%
on 08/26/26
+17.93 (+13.74%)
since 07/27/26
3-Month
121.39 +22.30%
on 06/10/26
149.62 -0.78%
on 08/26/26
+14.76 (+11.04%)
since 05/27/26
52-Week
108.46 +36.88%
on 10/02/25
157.29 -5.62%
on 02/11/26
+34.54 (+30.32%)
since 08/27/25

Most Recent Stories

More News
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Annual Healthcare Conference on Wednesday,...

GILD : 148.82 (+0.49%)
ITOC Stockholders Have Rights – If You Lost Money Investing in iTonic Holdings Ltd. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Pheton Holdings Ltd (NASDAQ: PTHL) (n/k/a...

GILD : 148.82 (+0.49%)
ITOC : 0.2792 (-3.66%)
PTHL : 0.9023 (+105.16%)
3 Unprofitable Stocks with Questionable Fundamentals

3 Unprofitable Stocks with Questionable Fundamentals

CLAR : 3.72 (-0.27%)
CNXC : 28.74 (+3.16%)
GILD : 148.82 (+0.49%)
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

– European Approval Received for Trodelvy plus Pembrolizumab in First-Line PD-L1-Positive Metastatic Triple-Negative Breast Cancer (TNBC) – – Approval...

GILD : 148.82 (+0.49%)
Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC

SAN DIEGO , Aug. 14, 2026 /PRNewswire/ -- Robbins LLP  reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired...

GILD : 148.82 (+0.49%)
ITOC : 0.2792 (-3.66%)
PTHL : 0.9023 (+105.16%)
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

GILD : 148.82 (+0.49%)
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment...

MGNX : 4.10 (+1.49%)
GILD : 148.82 (+0.49%)
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call

5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call

GILD : 148.82 (+0.49%)
3 Healthcare Stocks with Open Questions

3 Healthcare Stocks with Open Questions

MYGN : 3.23 (+3.53%)
GILD : 148.82 (+0.49%)
SHC : 19.69 (+0.77%)
GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure

GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure

GILD : 148.82 (+0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 152.09
2nd Resistance Point 150.85
1st Resistance Point 149.47
Last Price 148.82
1st Support Level 146.86
2nd Support Level 145.62
3rd Support Level 144.24

See More

52-Week High 157.29
Last Price 148.82
Fibonacci 61.8% 138.64
Fibonacci 50% 132.88
Fibonacci 38.2% 127.11
52-Week Low 108.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.